NASDAQ:EQ Equillium (EQ) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free EQ Stock Alerts $1.65 +0.04 (+2.48%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$1.58▼$1.7150-Day Range$1.56▼$3.0052-Week Range$0.45▼$3.25Volume55,696 shsAverage Volume185,464 shsMarket Capitalization$58.18 millionP/E RatioN/ADividend YieldN/APrice Target$3.90 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Equillium alerts: Email Address Equillium MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside136.4% Upside$3.90 Price TargetShort InterestHealthy6.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.08) to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.25 out of 5 starsMedical Sector745th out of 910 stocksPharmaceutical Preparations Industry344th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingEquillium has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEquillium has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.27% of the float of Equillium has been sold short.Short Interest Ratio / Days to CoverEquillium has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Equillium has recently decreased by 3.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEquillium does not currently pay a dividend.Dividend GrowthEquillium does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EQ. Previous Next 0.6 News and Social Media Coverage Search Interest7 people have searched for EQ on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Equillium insiders have not sold or bought any company stock.Percentage Held by Insiders30.30% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.05% of the stock of Equillium is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Equillium are expected to decrease in the coming year, from ($0.08) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Equillium is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Equillium is -4.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEquillium has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The TradingPubAt first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”But if you want the stock with “Hotspot Dates” hitting NEXT WEEK… About Equillium Stock (NASDAQ:EQ)Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Read More EQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EQ Stock News HeadlinesApril 3, 2024 | businesswire.comEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Equillium on Strong Clinical Data and Potential Financial UpsidesApril 23, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”April 2, 2024 | msn.comBiotech Rallies Strongly On Second Consecutive Positive HeadlineApril 1, 2024 | finance.yahoo.comEquillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus NephritisMarch 27, 2024 | marketwatch.comEquillium Shares Fall After Swing to 4Q LossMarch 25, 2024 | investorplace.comEQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023March 25, 2024 | benzinga.comEquillium: Q4 Earnings InsightsApril 23, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”March 25, 2024 | businesswire.comEquillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical HighlightsMarch 22, 2024 | businesswire.comEquillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational ConferenceMarch 12, 2024 | msn.comBioXcel Therapeutics GAAP EPS of -$0.76 beats by $0.15, revenue of $0.38M misses by $0.36MMarch 3, 2024 | finance.yahoo.comROOT Sep 2024 7.500 putFebruary 24, 2024 | finance.yahoo.comSMCI Mar 2024 970.000 callFebruary 24, 2024 | finance.yahoo.comSMCI Mar 2024 765.000 callFebruary 24, 2024 | sg.finance.yahoo.comSMCI Mar 2024 800.000 putFebruary 23, 2024 | uk.finance.yahoo.comSMCI Feb 2024 1460.000 putFebruary 23, 2024 | finance.yahoo.comSMCI Mar 2024 695.000 putFebruary 23, 2024 | benzinga.comEquillium Stock (NASDAQ:EQ), Short Interest ReportFebruary 13, 2024 | finance.yahoo.comBiosimilar Interleukins ( IL-17, IL-23, IL-1, IL-5, IL-6 ) Global Market Report 2024 - Robust CAGR of 40% Predicted by 2028November 20, 2023 | finance.yahoo.comEQ Bank Card launches in Québec as Carte Banque EQNovember 15, 2023 | benzinga.comEquillium Stock (NASDAQ:EQ), Analyst Ratings, Price Targets, PredictionsNovember 13, 2023 | finance.yahoo.comEquillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of RheumatologyNovember 8, 2023 | finance.yahoo.comEquillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesNovember 6, 2023 | finance.yahoo.comEquillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of NephrologyNovember 2, 2023 | finance.yahoo.comEquillium, Inc. (EQ) Stock Historical Prices & Data - Yahoo FinanceNovember 1, 2023 | msn.comEquillium (EQ) Price Target Increased by 11.23% to 7.24See More Headlines Receive EQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EQ CUSIPN/A CIK1746466 Webequilliumbio.com Phone(858) 240-1200FaxN/AEmployees44Year FoundedN/APrice Target and Rating Average Stock Price Target$3.90 High Stock Price Target$5.00 Low Stock Price Target$2.80 Potential Upside/Downside+136.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,340,000.00 Net Margins-36.96% Pretax Margin-35.35% Return on Equity-51.82% Return on Assets-22.57% Debt Debt-to-Equity RatioN/A Current Ratio1.79 Quick Ratio1.79 Sales & Book Value Annual Sales$36.08 million Price / Sales1.61 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book2.58Miscellaneous Outstanding Shares35,260,000Free Float24,573,000Market Cap$58.18 million OptionableNot Optionable Beta1.62 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Daniel Mark Bradbury (Age 63)Executive Chairman Comp: $158kMr. Bruce D. Steel C.F.A. (Age 58)Co-Founder, President, CEO & Director Comp: $779.87kMs. Christine Zedelmayer M.B.A. (Age 54)P.M.P., Senior VP & COO Comp: $553.73kDr. Stephen Connelly Ph.D. (Age 42)Chief Scientific Officer & Director Comp: $571.32kMr. Jason A. Keyes (Age 53)Chief Financial Officer Penny TomSenior VP of Finance & Principal Accounting OfficerMr. Michael MooreVice President of Investor Relations & Corporate CommunicationsDr. Matthew Ritter Ph.D.Senior Vice President of Corporate DevelopmentMr. Joel M. Rothman (Age 55)Chief Development Officer Dr. Maple Fung M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsKronos BioNASDAQ:KRONMarinus PharmaceuticalsNASDAQ:MRNSLantern PharmaNASDAQ:LTRNLandos BiopharmaNASDAQ:LABPCelularityNASDAQ:CELUView All CompetitorsInstitutional OwnershipDecheng Capital LLCBought 4,447,308 shares on 2/12/2024Ownership: 12.663%View All Institutional Transactions EQ Stock Analysis - Frequently Asked Questions Should I buy or sell Equillium stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EQ shares. View EQ analyst ratings or view top-rated stocks. What is Equillium's stock price target for 2024? 2 equities research analysts have issued 12-month target prices for Equillium's stock. Their EQ share price targets range from $2.80 to $5.00. On average, they anticipate the company's stock price to reach $3.90 in the next twelve months. This suggests a possible upside of 136.4% from the stock's current price. View analysts price targets for EQ or view top-rated stocks among Wall Street analysts. How have EQ shares performed in 2024? Equillium's stock was trading at $0.7230 at the beginning of the year. Since then, EQ shares have increased by 128.2% and is now trading at $1.65. View the best growth stocks for 2024 here. When is Equillium's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our EQ earnings forecast. How were Equillium's earnings last quarter? Equillium, Inc. (NASDAQ:EQ) released its earnings results on Monday, March, 25th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.10. The company had revenue of $9.21 million for the quarter, compared to analyst estimates of $8.85 million. Equillium had a negative net margin of 36.96% and a negative trailing twelve-month return on equity of 51.82%. What is Geoffrey A. Rotstein's approval rating as Equillium's CEO? 10 employees have rated Equillium Chief Executive Officer Geoffrey A. Rotstein on Glassdoor.com. Geoffrey A. Rotstein has an approval rating of 50% among the company's employees. This puts Geoffrey A. Rotstein in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 76.0% of employees surveyed would recommend working at Equillium to a friend. When did Equillium IPO? Equillium (EQ) raised $70 million in an initial public offering on Friday, October 12th 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO. How do I buy shares of Equillium? Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EQ) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
